RecruitingNCT06725706

Beta Amyloid PET/CT in Various Aβ-Related Disease


Sponsor

Tianjin Medical University

Enrollment

500 participants

Start Date

Sep 1, 2012

Study Type

OBSERVATIONAL

Conditions

Summary

To evaluate the potential usefulness of 18F-92/AV45, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria1

  • \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria1

  • \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Interventions

DIAGNOSTIC_TEST18F-92/AV45, 11C-PIB

Each subject receive a single intravenous injection of 18F-92/AV45, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.


Locations(3)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China

Chinese PLA General Hospital,

Beijing, Beijing Municipality, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06725706


Related Trials